BiomX (PHGE) Stock Price, News & Analysis

Company Overview

BiomX Inc. is a clinical-stage biotechnology company developing precision therapies that target harmful bacteria while seeking to preserve beneficial components of the microbiome. The company’s platform uses bacteriophages, naturally occurring viruses that selectively infect and destroy specific bacterial strains, to address diseases associated with bacterial imbalances or persistent infections.

BiomX’s development programs have included BX004, an inhaled phage therapy designed to target Pseudomonas aeruginosa infections associated with cystic fibrosis, and BX211, a candidate intended to target bacteria implicated in ulcerative colitis. The company has also worked on phage-based approaches for other chronic and infectious diseases, including programs focused on identifying and eliminating disease-associated bacterial strains.

BiomX was founded in Israel and has conducted research and clinical development activities in Israel, the United States and other international locations. The company’s operations have been supported by collaborations with academic and clinical institutions as it advances its microbiome-focused therapeutics. Jonathan Solomon has served as chief executive officer and has been associated with the company’s development of targeted bacteriophage treatments.

Key Stats

• Today's Range: $1.65 to $2.16
• 50-Day Range: $1.31 to $2.10
• 52-Week Range: $1.19 to $122.93
• Volume: 3.33 million shs
• Average Volume: 364,372 shs
• Market Capitalization: $4.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $260.00
• Consensus Rating: Hold

BiomX Stock Analysis - MarketRank™

BiomX scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

BiomX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

BiomX has a consensus price target of $260.00, representing about 13,954.1% upside from its current price of $1.85.

Amount of Analyst Coverage

BiomX has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BiomX are expected to decrease in the coming year, from ($58.50) to ($60.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BiomX is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BiomX is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.34% of the float of BiomX has been sold short.

Short Interest Ratio / Days to Cover

BiomX has a short interest ratio ("days to cover") of 0.59, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BiomX has recently increased by 83.27%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BiomX does not currently pay a dividend.

Dividend Growth

BiomX does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BiomX insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.23% of the stock of BiomX is held by insiders.

Percentage Held by Institutions

40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/19/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:PHGE
• Previous Symbol: NYSEMKT:PHGE
• CIK: 1739174
• Web: www.biomx.com
• Phone: 972-7-2394-2377
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BiomX: $260.00
• High Price Target: $260.00
• Low Price Target: $260.00
• Potential Upside/Downside: +13,954.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.20 million
• Net Margins: N/A
• Pretax Margin: -13,700.30%
• Return on Equity: N/A
• Return on Assets: -165.38%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 0.24
• Quick Ratio: 0.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($124.99) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 2,670,000
• Free Float: 2,666,000
• Market Cap: $4.94 million
• Optionable: N/A
• Beta: 1.33